Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Accumulated Expenses (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Accumulated Expenses for 4 consecutive years, with $11.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 77.73% to $11.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.1 million, a 77.73% increase, with the full-year FY2024 number at $17.5 million, up 72.05% from a year prior.
  • Accumulated Expenses was $11.1 million for Q3 2025 at Century Therapeutics, down from $11.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $17.5 million in Q4 2024 to a low of $117000.0 in Q4 2022.
  • A 4-year average of $7.3 million and a median of $7.2 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 8574.36% in 2023, then tumbled 60.91% in 2025.
  • Century Therapeutics' Accumulated Expenses stood at $117000.0 in 2022, then skyrocketed by 8574.36% to $10.1 million in 2023, then skyrocketed by 72.05% to $17.5 million in 2024, then tumbled by 36.71% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Accumulated Expenses are $11.1 million (Q3 2025), $11.7 million (Q2 2025), and $2.9 million (Q1 2025).